Novartis' iptacopan meets PhIII test in fight against rare blood disease

Novartis declared a Phase III success for its drug iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria, a rare disorder in which flawed red blood cells are attacked by the immune system, forcing patients to get blood transfusions.